1. Home
  2. LIQT vs AKTX Comparison

LIQT vs AKTX Comparison

Compare LIQT & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LiqTech International Inc.

LIQT

LiqTech International Inc.

HOLD

Current Price

$0.40

Market Cap

17.2M

Sector

Technology

ML Signal

HOLD

Logo Akari Therapeutics plc ADS

AKTX

Akari Therapeutics plc ADS

SELL

Current Price

$8.54

Market Cap

15.4M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
LIQT
AKTX
Founded
2004
N/A
Country
Denmark
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.2M
15.4M
IPO Year
2011
2014

Fundamental Metrics

Financial Performance
Metric
LIQT
AKTX
Price
$0.40
$8.54
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $25.50
AVG Volume (30 Days)
★ 148.4K
45.4K
Earning Date
11-12-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
$21.16
N/A
Revenue Next Year
$22.50
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.42
$0.12
52 Week High
$3.35
$29.32

Technical Indicators

Market Signals
Indicator
LIQT
AKTX
Relative Strength Index (RSI) 36.35 42.52
Support Level $0.42 $6.51
Resistance Level $0.71 $10.98
Average True Range (ATR) 0.08 0.93
MACD -0.01 -0.15
Stochastic Oscillator 3.01 16.41

Price Performance

Historical Comparison
LIQT
AKTX

About LIQT LiqTech International Inc.

LiqTech International Inc is a clean technology company which provides technology for gas and liquid purification by manufacturing ceramic silicon carbide filters. The company is renowned in three business areas: ceramic membranes and membrane incorporated liquid filtration systems, ceramic diesel particulate filters (DPFs) to control soot exhaust particles and black carbon emission from diesel engines, and plastic components for usage across various industries. The company's product portfolio consists of ceramic silicon membranes for liquid filtration, diesel particulate filters, Hybrid Technology Membranes and others. The Company operates through three reportable segments: Systems and Aftermarket, Filters and Membranes, and Components.

About AKTX Akari Therapeutics plc ADS

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.

Share on Social Networks: